Related Experiment Video
Updated: May 26, 2025

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
HDAC6 deficiency aggravates ductular reactions through aggresome-mediated hepatocyte apoptosis
Shanshan Tan1, Guoquan Fu2, Yixia Xie1
1School of Life and Environmental Sciences, Shaoxing University, Shaoxing, Zhejiang, 312000, China.
Insights
Histone deacetylase 6 (HDAC6) deficiency worsens liver ductular reactions and fibrosis by promoting aggresome formation and hepatocyte apoptosis. This highlights HDAC6
Area of Science:
- Hepatology and molecular biology
- Liver disease pathogenesis
- Cellular stress response
Background:
- Ductular reactions (DRs) are key in liver disease development.
- Histone deacetylase 6 (HDAC6) regulates tissue repair but its role in DRs is unknown.
Purpose of the Study:
- To investigate the role and mechanism of HDAC6 in liver ductular reactions.
- To determine the effect of HDAC6 deficiency on liver fibrosis and hepatocyte apoptosis.
Main Methods:
- Utilized HDAC6 knockout male mice and DDC-induced liver injury model.
- Assessed aggresome formation in hepatocytes using tubastatin A (TSA).
- Quantified protein and gene expression via immunohistochemistry and qRT-PCR.
Main Results:
- HDAC6 deficiency exacerbated DRs and fibrosis, increasing TGF-β and Notch signaling.
- HDAC6 knockout/inhibition promoted hepatocyte apoptosis (elevated caspase3, caspase9, p53).
- TSA treatment induced aggresome formation in hepatocytes, encased by vimentin.
Conclusions:
- HDAC6 deficiency promotes DRs and liver fibrosis via intracellular aggregate formation.
- This process leads to increased hepatocyte apoptosis.
- HDAC6 plays a protective role in mitigating liver injury and fibrosis.
Abstract:
Ductular reactions (DRs) contribute significantly to the occurrence and development of liver disease. While histone deacetylase 6 (HDAC6) is known to regulate injury repair in multiple tissues, its exact role in DRs remains unclear. This study examined the role and underlying mechanism of HDAC6 in DRs using an HDAC6 knockout (HDAC6-/y) male mouse model. Wild type and HDAC6-deficient male mice were administered 3,5 diethoxicarbonyl-1,4 dihydrocollidine (DDC) to induce DRs. The impact of HDAC6 inhibition on aggresome formation was assessed in vitro using AML-12 hepatocytes exposed to H2O2 and treated with tubastatin A (TSA), a selective HDAC6 inhibitor. Fluorescence immunohistochemistry and quantitative real-time polymerase chain reaction (qRT-PCR) were employed to quantify protein and gene expression levels, respectively. Immunohistochemical and qRT-PCR analyses revealed that HDAC6 deficiency exacerbated DRs and fibrosis, accompanied by increased expression of transforming growth factor β (TGF-β) and activation of the Notch signaling pathway. Additionally, genetic knockout or pharmacological inhibition of HDAC6 promoted hepatocyte apoptosis in vivo and in vitro, as evidenced by elevated caspase3, caspase9, and p53 expression. Furthermore, TSA treatment induced the formation of aggresomes in H2O2-exposed AML-12 hepatocytes, which were encased by vimentin filaments. These findings demonstrate that HDAC6 deficiency promotes DRs and liver fibrosis through the formation of intracellular aggregates, ultimately leading to hepatocyte apoptosis.

